Skip to main content

Advertisement

SpringerLink
Log in

Medullary thyroid carcinoma

  • Published:
Current Treatment Options in Oncology Aims and scope Submit manuscript

Opinion statement

Medullary thyroid carcinoma (MTC) is a neuroendocrine malignancy that occurs in hereditary (25%) and sporadic (75%) clinical settings. MTC is present in all patients with the multiple endocrine neoplasia type 2 syndromes. MTCs produce calcitonin, the measurement of which can indicate the presence of tumors in people who are at risk and the effectiveness of therapy in treated patients. Surgical cure is possible in young patients with multiple endocrine neoplasia type 2 who undergo preventative thyroidectomy (approximately 50% of patients who are diagnosed with a palpable thyroid mass) and in some patients with recurrent nodal metastatic disease in the neck. Mortality from MTC is caused by tumor invasion of the trachea, great vessels in the neck, or mediastinum or by the effects of distant metastatic disease. Surgery for cervical recurrence can prevent death from tracheal invasion. The role of radiation therapy is not well defined. There is no effective systemic therapy for MTC. Activating mutations in a tyrosine kinase receptor gene (RET) are present in most MTCs, and experience with tyrosine kinase inhibitors and other agents in clinical trials is critical for the identification of effective systemic treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Moley JF, DeBenedetti MK: Patterns of nodal metastases in palpable medullary thyroid carcinoma: recommendations for extent of node dissection. Ann Surg 1999, 229:880–887. This paper discusses the nodal drainage of the thyroid and the findings in regional nodes in a large series of patients who had removal of central and bilateral nodes (levels I-V) in operations for MTC. The paper provides guidelines for the extent of resection.

    Article  PubMed  CAS  Google Scholar 

  2. Moley JF, Lairmore TC, Phay JE: Hereditary endocrinopathies. Curr Probl Surg 1999, 36:653–762.

    Article  PubMed  CAS  Google Scholar 

  3. Mulligan L, Kwok J, Healy C: Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A (MEN 2A). Nature 1993, 363:458–460.

    Article  PubMed  CAS  Google Scholar 

  4. Donis-Keller H, Dous S, Chi D, et al.: Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1993, 2:851–856.

    Article  PubMed  CAS  Google Scholar 

  5. Cohen MS, Phay JE, Albinson C, et al.: Gastrointestinal manifestations of multiple endocrine neoplasia type 2. Ann Surg 2002, 235:648–654.

    Article  PubMed  Google Scholar 

  6. O’Riordain DS, O’Brien T, Crotty TB, et al.: Multiple endocrine neoplasia type 2B: more than an endocrine disorder. Surgery 1995, 118:936–942.

    Article  PubMed  CAS  Google Scholar 

  7. Gagel RF, Tashjian AH Jr, Cummings T, et al.: The clinical outcome of prospective screening for multiple endocrine neoplasia type 2A, an 18 year experience. N Engl J Med 1988, 318:478–484.

    Article  PubMed  CAS  Google Scholar 

  8. Wells SA Jr, Chi DD, Toshima K, et al.: Predictive DNA testing and prophylactic thyroidectomy in patients at risk for multiple endocrine neoplasia type 2A. Ann Surg 1994, 220:237–247.

    Article  PubMed  Google Scholar 

  9. Lips CJ, Landsvater RM, Hoppener JW, et al.: Clinical screening as compared with DNA analysis in families with multiple endocrine neoplasia type 2A. N Engl J Med 1994, 331:828–835.

    Article  PubMed  CAS  Google Scholar 

  10. Sizemore GW, Heath H, Carney JA: Multiple endocrine neoplasia type 2. Clin Endocrinol Metab 1980, 9:299–315.

    PubMed  CAS  Google Scholar 

  11. Dralle H, Gimm O, Simon D, et al.: Prophylactic thyroidectomy in 75 children with hereditary medullary thyroid carcinoma: German and Austrian experience. World J Surg 1998, 22:744–751.

    Article  PubMed  CAS  Google Scholar 

  12. Dralle H: Lymph node dissection and medullary thyroid carcinoma. Br J Surg 2002, 89:1073–1075. This report describes this author’s extensive personal experience with cervical and mediastinal operations for MTC.

    Article  PubMed  CAS  Google Scholar 

  13. Weber T, Schilling T, Frank-Raue K, et al.: Impact of modified radical neck dissection on biochemical cure in medullary thyroid carcinomas. Surgery 2001, 130:1044–1049. This paper describes the approach to MTC from a large American cancer center.

    Article  PubMed  CAS  Google Scholar 

  14. Dralle H, Damm I, Scheumann GF, et al.: Compartment-oriented microdissection of regional lymph nodes in medullary thyroid carcinoma. Surg Today 1994, 24:112–121.

    Article  PubMed  CAS  Google Scholar 

  15. Decker RA, Geiger JD, Cox CE, et al.: Prophylactic surgery for multiple endocrine neoplasia type IIa after genetic diagnosis: is parathyroid transplantation indicated? World J Surg 1996, 20:814–820.

    Article  PubMed  CAS  Google Scholar 

  16. Russell CF, van Heerden JA, Sizemore GW, et al.: The surgical management of medullary carcinoma. Ann Surg 1983, 197:42–48.

    PubMed  CAS  Google Scholar 

  17. Olson JA Jr, DeBenedetti MK, Baumann DS, Wells SA Jr: Parathyroid autotransplantation during thyroidectomy: results of long-term follow-up. Ann Surg 1996, 223:472–477.

    Article  PubMed  Google Scholar 

  18. Wells SA, Ross AJ, Dale JK, Gray RS: Transplantation of the parathyroid glands: current status. Surg Clin North Am 1979, 59:167–177.

    PubMed  Google Scholar 

  19. Wells SA Jr, Skinner MA: Prophylactic thyroidectomy, based on direct genetic testing, in patients at risk for the multiple endocrine neoplasia type 2 syndromes. Exp Clin Endocrinol Diabetes 1998, 106:29–34.

    PubMed  CAS  Google Scholar 

  20. Block MA, Jackson CE, Greenwalk KA, et al.: Clinical characteristics distinguishing hereditary from sporadic medullary thyroid carcinoma. Arch Surg 1980, 115:142–148.

    PubMed  CAS  Google Scholar 

  21. Stepanas AV, Samaan NA, Hill CS Jr, Hickey RC: Medullary thyroid carcinoma: importance of serial serum calcitonin measurement. Cancer 1979, 43:825–837.

    Article  PubMed  CAS  Google Scholar 

  22. van Heerden JA, Grant CS, Gharib H, et al.: Long-term course of patients with persistent hypercalcitoninemia after apparent curative primary surgery for medullary thyroid carcinoma. Ann Surg 1990, 212:395–401. This paper describes the long-term outcome in a group of patients with elevated calcitonin levels after surgery and provides a rationale for observation rather than aggressive treatment of this problem.

    Article  PubMed  Google Scholar 

  23. Normann T, Gautvik KM, Johannessen JV, Brennhovd IO: Medullary carcinoma of the thyroid in Norway. Acta Endocrinol 1976, 83:71–85.

    PubMed  CAS  Google Scholar 

  24. O’Riordain DS, O’Brien T, Weaver AL, et al.: Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B. Surgery 1994, 116:1017–1023.

    PubMed  CAS  Google Scholar 

  25. Tung WS, Vesely TM, Moley JF: Laparoscopic detection of hepatic metastases in patients with residual or recurrent medullary thyroid cancer. Surgery 1995, 118:1024–1029. This paper describes the success of diagnostic laparoscopy and liver evaluation in localizing occult metastatic disease in patients with elevated calcitonin levels after treatment of MTC.

    Article  PubMed  CAS  Google Scholar 

  26. Cohen MS, DeBenedetti M, Moley JF: Laparoscopic liver evaluation for recurrent medullary thyroid carcinoma. Paper presented at the Annual Meeting of the Society of Surgical Oncology. Los Angeles, CA; 2003.

  27. Norton J, Doppman J, Brennan M: Localization and resection of clinically inapparent medullary carcinoma of the thyroid. Surgery 1980, 87:616–622.

    PubMed  CAS  Google Scholar 

  28. Block M, Jackson C, Tashjian A: Management of occult medullary thyroid carcinoma: evidenced only by serum calcitonin level elevations after apparently adequate neck operations. Arch Surg 1992, 113:368–372.

    Google Scholar 

  29. Buhr H, Kallinowski F, Raue F, et al.: Microsurgical neck dissection for occultly metastasizing medullary thyroid carcinoma: three year results. Cancer 1993, 72:3685–3693.

    Article  PubMed  CAS  Google Scholar 

  30. Tisell L, Hansson G, Jansson S, Salander H: Reoperation in the treatment of asymptomatic metastasizing medullary thyroid carcinoma. Surgery 1986, 99:60–66.

    PubMed  CAS  Google Scholar 

  31. Moley JF, Wells SA, Dilley WG, Tisell LE: Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 1993, 114:1090–1095.

    PubMed  CAS  Google Scholar 

  32. Moley J, Dilley W, DeBenedetti M: Improved results of cervical reoperation for medullary thyroid carcinoma. Ann Surg 1997, 225:734–743. This paper describes the author’s initial personal experience with reoperation for MTC.

    Article  PubMed  CAS  Google Scholar 

  33. Husain M, Alsever RN, Lock JP, et al.: Failure of medullary carcinoma of the thyroid to respond to doxorubicin therapy. Horm Res 1978, 9:22–25.

    Article  PubMed  CAS  Google Scholar 

  34. Scherubl H, Raue F, Ziegler R: Combination chemotherapy of advanced medullary and differentiated thyroid cancer: phase II study. J Cancer Res Clin Oncol 1990, 116:21–23.

    Article  PubMed  CAS  Google Scholar 

  35. Orlandi F, Caraci P, Berruti A, et al.: Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer. Ann Oncol 1994, 5:763–765.

    PubMed  CAS  Google Scholar 

  36. Schlumberger M, Abdelmoumene N, Delisle MJ, Couette JE: Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FUstreptozocin and 5 FU-dacarbazine. Br J Cancer 1995, 71:363–365. This paper summarizes the authors’ experience with chemotherapy for MTC. There are few responses and many patients with stable disease, but many patients will have stable disease even if nothing is done [22].

    PubMed  CAS  Google Scholar 

  37. Grohn P, Kumpulainen E, Jakobsson M: Response of medullary thyroid cancer to low-dose alpha-interferon therapy. Acta Oncol 1990, 29:950–951.

    PubMed  CAS  Google Scholar 

  38. Juweid ME, Hajjar G, Stein R, et al.: Initial experience with high-dose radioimmunotherapy of metastatic medullary thyroid cancer using 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen MAb and AHSCR. J Nucl Med 2000, 41:93–103.

    PubMed  CAS  Google Scholar 

  39. Schott M, Feldkamp J, Klucken M, et al.: Calcitonin-specific antitumor immunity in medullary thyroid carcinoma following dendritic cell vaccination. Cancer Immunol Immunother 2002, 51:663–668.

    Article  PubMed  CAS  Google Scholar 

  40. Mahler C, Verheist J, Delouneville M, et al.: Long-term treatment of metastatic medullary thyroid carcinoma with the somatostatin analogue octreotide. Clin Endocrinol 1990, 33:261.

    CAS  Google Scholar 

  41. Smid WM, Dullaart RP: Octreotide for medullary thyroid carcinoma associated diarrhea. Neth J Med, 1992. 40:240–243.

    PubMed  CAS  Google Scholar 

  42. Vitale G, Tagliaferri P, Caraglia M, et al.: Slow release lanreotide in combination with interferon-alpha 2b in the treatment of symptomatic advanced medullary thyroid carcinoma. J Clin Endocrinol Metab 2000, 85:983–988.

    Article  PubMed  CAS  Google Scholar 

  43. Cohen MS, Hussain HB, Moley JF: Inhibition of medullary thyroid carcinoma cell proliferation and RET phosphorylation by tyrosine kinase inhibitors. Surgery 2002, 132:960–966.

    Article  PubMed  Google Scholar 

  44. Carlomagno F, Vitagliano D, Guida T, et al.: ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002, 62:7284–7290.

    PubMed  CAS  Google Scholar 

  45. Carlomagno F, Vitagliano D, Guida T, et al.: The kinase inhibitor PP1 blocks tumorigenesis induced by RET oncogenes. Cancer Res 2002, 62:1077–1082.

    PubMed  CAS  Google Scholar 

  46. Saad M, Guido J, Samaan N: Radioactive iodine in the treatment of medullary carcinoma of the thyroid. J Clin Endocrinol Metab 1983, 57:124–128.

    Article  PubMed  CAS  Google Scholar 

  47. Brierley JD, Tsang RW: External radiation therapy in the treatment of thyroid malignancy. Endocrinol Metab Clin North Am 1996, 25:141–157. This review summarizes the radiation therapy experience in MTC.

    Article  PubMed  CAS  Google Scholar 

  48. Nguyen T, Chassard JL, Lagarde P, et al.: Results of postoperative radiation therapy in medullary carcinoma of the thyroid: a retrospective study by the French Federation of Cancer Institutes—the Radiotherapy Cooperative Group. Radiother Oncol 1992, 23:1–5.

    Article  PubMed  CAS  Google Scholar 

  49. Samaan NA, Schultz PN, Hickey RC: Medullary thyroid carcinoma: prognosis of familial versus nonfamilial disease and the role of radiotherapy. Horm Metab Res Suppl 1989, 21:21–25.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Endocrine and Oncologic Surgery, Siteman Cancer Center, Washington University School of Medicine, 660 South Euclid, Box 8109, 63110, St. Louis, MO, USA

    Jeffrey F. Moley MD

Authors
  1. Jeffrey F. Moley MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Moley, J.F. Medullary thyroid carcinoma. Curr. Treat. Options in Oncol. 4, 339–347 (2003). https://doi.org/10.1007/s11864-003-0009-8

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11864-003-0009-8

Keywords

Search

Navigation